The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance)
Open accessAbstract
PURPOSE: To determine the predictive and prognostic value of the consensus molecular subtypes (CMSs) of colorectal cancer (CRC) that represent a merging of gene expression–based features largely in primary tumors from six independent classification systems and provide a framework for capturing the intrinsic heterogeneity of CRC in patients enrolled in CALGB/SWOG 80405. PATIENTS AND METHODS: CALGB/SWOG 80405 is a phase III trial that compared the addition of bevacizumab or cetuximab to infusional fluorouracil, leucovorin, and oxaliplatin or fluorouracil, leucovorin, and irinotecan as first-line treatment of advanced CRC. We characterized the CMS classification using a novel NanoString gene expression panel on primary CRCs from 581 patients enrolled in this study to assess the prognostic and predictive value of CMSs in these patients. RESULTS: The CMSs are highly prognostic for overall survival (OS; P < .001) and progression-free survival (PFS; P < .001). Furthermore, CMSs were predictive for both OS ( P for interaction < .001) and PFS ( P for interaction = .0032). In the CMS1 cohort, patients treated with bevacizumab had a significantly longer OS than those treated with cetuximab ( P < .001). In the CMS2 cohort, patients treated with cetuximab had a significantly longer OS than patients treated with bevacizumab ( P = .0046). CONCLUSION: These findings highlight the possible clinical utility of CMSs and suggests that refinement of the CMS classification may provide a path toward identifying patients with metastatic CRC who are most likely to benefit from specific targeted therapy as part of the initial treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“bevacizumab is effective regardless of RAS gene status”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regularization Paths for Generalized Linear Models via Coordinate Descent
Friedman, J., Hastie, T., & Tibshirani, R. (2010) · Journal of Statistical Software · doi:10.18637/jss.v033.i01 · Cited by 19,927
On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other
Mann, H. B., & Whitney, D. R. (1947) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177730491 · Cited by 14,320
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citationColorectal cancer statistics, 2017
Siegel, R. L., Miller, K. D., Fedewa, S. A., Ahnen, D. J., Meester, R. G. S., Barzi, A., & Jemal, A. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21395 · Cited by 3,807
Cancer treatment and survivorship statistics, 2012
Siegel, R. L., Desantis, C. E., Virgo, K. S., Stein, K., Mariotto, A. B., Smith, T. G., Cooper, D. L., Gansler, T. S., Lerro, C. C., Fedewa, S. A., et al. (2012) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,979
Cancer treatment and survivorship statistics, 2014
Desantis, C. E., Lin, C. C., Mariotto, A. B., Siegel, R. L., Stein, K., Kramer, J. L., Alteri, R., Robbins, A. S., & Jemal, A. (2014) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21235 · Cited by 2,847
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Marisa, L., de Reyniès, A., Duval, A., Selves, J., Gaub, M. P., Vescovo, L., Etienne-Grimaldi, M.-C., Schiappa, R., Guenot, D., Ayadi, M., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001453 · Cited by 1,507
Immunogenic death of colon cancer cells treated with oxaliplatin
Tesnière, A., Schlemmer, F., Boige, V., Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apétoh, L., Barault, L., et al. (2009) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,224
The $\chi^2$ Test of Goodness of Fit
Cochran, W. G. (1952) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177729380 · Cited by 1,145
Cremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00122-9 · Cited by 1,092
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Motz, G. T., Santoro, S. P., Wang, L., Garrabrant, T., Lastra, R. R., Hagemann, I. S., Lal, P., Feldman, M. D., Benencia, F., & Coukos, G. (2014) · Nature Medicine · doi:10.1038/nm.3541 · Cited by 1,074
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016
Sadanandam, A., Lyssiotis, C. A., Homicsko, K., Collisson, E. A., Gibb, W. J., Wullschleger, S., Ostos, L. C. G., Lannon, W. A., Grotzinger, C., Del Rio, M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3175 · Cited by 960
Venook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Fruth, B., Meyerhardt, J. A., Schrag, D., Greene, C., O'Neil, B. H., Atkins, J. N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7105 · Cited by 898 · cited 3×
“PATIENTS AND METHODS CALGB/SWOG 80405 This trial was conducted to determine the relative efficacy of cetuximab versus bevacizumab when added to standard modified FOLFOX or FOLFIRI as first-line therapy in advanced or KRAS wild-type mCRC.(4) The trial was initially designed to compare three strategies: chemotherapy plu…”
BackgroundMethodInfluentialSelf-citationArnold, D., Lueza, B., Douillard, J.-Y., Peeters, M., Lenz, H., Venook, A. P., Heinemann, V., Cutsem, E. V., Pignon, J., Tabernero, J. M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx175 · Cited by 853
Self-citationMutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T., Sheng, K., Dobrolecki, L. E., Zhang, X., Putluri, N., et al. (2017) · Nature · doi:10.1038/nature21724 · Cited by 841
From tumour heterogeneity to advances in precision treatment of colorectal cancer
Punt, C. J. A., Koopman, M., & Vermeulen, L. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.171 · Cited by 654 · cited 1×
“These insights have the potential to help treating physicians to use an individual’s tumor molecular makeup to predict likely sensitivity and resistance to targeted therapies.(9,10) ASSOCIATED CONTENT See accompanying Editorial on page 1847 Appendix Data Supplements Author affiliations and support information (if appl…”
BackgroundDistal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
Missiaglia, E., Jacobs, B., D’Ario, G., Narzo, A. F. D., Soneson, C., Budínská, E., Popovici, V. C., Vecchione, L., Gerster, S., Yan, P., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu275 · Cited by 646
Self-citationBecht, E., de Reyniès, A., Giraldo, N. A., Pilati, C., Buttard, B., Lacroix, L., Selves, J., Sautès-Fridman, C., Laurent-Puig, P., & Fridman, W. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2879 · Cited by 590
The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer
Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., et al. (2015) · Nature · doi:10.1038/nature14969 · Cited by 479
Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
Loupakis, F., Yang, D., Yau, L., Feng, S., Cremolini, C., Zhang, W., Maus, M. K. H., Antoniotti, C., Langer, C., Scherer, S. J., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju427 · Cited by 477
Self-citationPeterson, T. E., Kirkpatrick, N. D., Huang, Y., Farrar, C. T., Marijt, K. A., Kloepper, J., Datta, M., Amoozgar, Z., Seano, G., Jung, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525349113 · Cited by 317
Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes
Stintzing, S., Tejpar, S., Gibbs, P., Thiebach, L., & Lenz, H. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.016 · Cited by 278
Self-citationStintzing, S., Wirapati, P., Lenz, H., Neureiter, D., von Weikersthal, L. F., Decker, T. W., Kiani, A., Kaiser, F., Al‐Batran, S., Heintges, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz387 · Cited by 196
Self-citationTrinh, A., Trumpi, K., De Sousa E Melo, F., Wang, X., de Jong, J. H., Fessler, E., Kuppen, P. J. K., Reimers, M. S., Swets, M., Koopman, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0680 · Cited by 180
Genomics and emerging biomarkers for immunotherapy of colorectal cancer
Kather, J. N., Halama, N., & Jaeger, D. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.010 · Cited by 154
Mooi, J. K., Wirapati, P., Asher, R., Lee, C. K., Savas, P. S., Price, T. J., Townsend, A. R., Hardingham, J. E., Buchanan, D. D., Williams, D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy410 · Cited by 144
Self-citationFan, C., Chen, T., Shang, Y.-N., Gu, Y.-Z., Zhang, S. L., Lu, R., OuYang, S.-R., Zhou, X., Li, Y., Wt, M., et al. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.337 · Cited by 62
Modest, D. P., Stintzing, S., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al‐Batran, S., Heintges, T., Kahl, C., Seipelt, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22396 · Cited by 50
Tel, J., Hato, S. V., Torensma, R., Buschow, S. I., Figdor, C. G., Lesterhuis, W. J., & de Vries, I. J. M. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1189-x · Cited by 49
Michielsen, A. J., Noonan, S. A., Martin, P., Tosetto, M., Marry, J., Biniecka, M., Maguire, A. A., Hyland, J. M., Sheahan, K. D., O’Donoghue, D. P., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0162 · Cited by 45
Flagged first, then by citations
Research works printed but not linked: 1
- Mantel N, 1966, Cancer Chemother Rep, 50, 163
Cited by
Sorted by citations
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Clinical management of metastatic colorectal cancer in the era of precision medicine
Ciardiello, F., Ciardiello, D., Martini, G., Napolitano, S., Tabernero, J. M., & Cervantes, A. M. R. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21728 · Cited by 556
Eng, C., Yoshino, T., Ruíz‐García, E., Mostafa, N., Cann, C., O’Brian, B., Benny, A., Perez, R. O., & Cremolini, C. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00360-x · Cited by 508
Biomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges
Koncina, E., Haan, S., Rauh, S., & Letellier, E. (2020) · Cancers · doi:10.3390/cancers12020319 · Cited by 272
Metadata
- Authors
- Lenz, H.-J., Ou, F.-S., Venook, A. P., Hochster, H. S., Niedzwiecki, D., Goldberg, R. M., Mayer, R. J., Bertagnolli, M. M., Blanke, C. D., Zemla, T., Qu, X., Wirapati, P., Tejpar, S., Innocenti, F., & Kabbarah, O.
- Affiliations
- USC Norris Comprehensive Cancer Center (US)
- Mayo Clinic (US)
- University of California, San Francisco (US)
- Yale Cancer Center, New Haven, CT
- Duke Medical Center (US)
- West Virginia University (US)
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- Oregon Health & Science University (US)
- Genentech (US)
- SIB Swiss Institute of Bioinformatics (CH)
- Universitair Ziekenhuis Leuven (BE)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2019-08-01
- Volume
- 37
- Issue
- 22
- Pages
- 1876-1885
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC6675593
- OpenAlex
- W2943196840
- Cited by
- 246
- References
- 35
- Citations by year
- 2026: 11 · 2025: 31 · 2024: 28 · 2023: 27 · 2022: 39 · 2021: 61 · 2020: 37 · 2019: 8
- FWCI
- 15.13
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-02-07)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- Funders
- Eli Lilly and Company
- Pfizer
- Bayer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Teva Pharmaceutical Industries
- Baxalta
- Taiho Pharmaceutical
- Exelixis
- Jazz Pharmaceuticals
- Leidos
- BeiGene
- Incyte
- Eisai
- National Institutes of Health (UL1TR001863)
- Genentech
- Takeda Oncology
- Pharmacyclics
- National Cancer Institute (U10CA180882, U10CA180820, U10CA180791, UG1CA233290, U10CA180888, U10CA180836, U10CA180790, UG1CA233331, UG1CA233180, U10CA180830, U10CA180795, U10CA180850, U10CA180838, U10CA180867, U10CA180821, UG1CA180830, U10CA180799)
- National Institute of General Medical Sciences (U54GM104942)
- National Center for Advancing Translational Sciences
- Janssen Pharmaceuticals
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- consensus molecular subtypes, metastatic colorectal cancer, prognostic factors, predictive biomarkers, bevacizumab, cetuximab, first-line chemotherapy, overall survival, progression-free survival, targeted therapy selection
- MeSH terms
- Bevacizumab, Cetuximab, Irinotecan, Oxaliplatin, Aged, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Neoplasm Metastasis, Predictive Value of Tests, Prognosis, Colorectal Neoplasms, Gene Expression Regulation, Neoplastic, Treatment Outcome, Disease-Free Survival, Gene Expression Profiling, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
